Could your own blood cells ease knee arthritis pain?

NCT ID NCT07703280

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This clinical trial tests whether injecting a person's own purified blood cells into the knee can reduce pain and improve movement in people with knee osteoarthritis. The study compares two doses of these cells against a standard steroid injection. Participants are adults aged 40 to 80 with moderate to severe knee pain and x-ray evidence of arthritis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an injection of a person's own purified blood cells (PCP-PBMCs)
What this could lead to
If successful, this approach could offer a new, long-lasting treatment for knee osteoarthritis pain without surgery or repeated steroid injections.
What could go wrong
This is an early-to-mid-stage trial, so the treatment may not prove more effective than the steroid comparison. Risks include injection-related reactions and the possibility that benefits are temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tibiofemoral osteophytes on x-ray (Kellgren-Lawrence grade of 2-4) * Age ≥ 40 and ≤ 80 years. * Moderate to severe knee pain * Reduced joint space width at the medial part of the knee compared to the lateral part under x-ray examination. If standing is not feasible, the same supine position must be used consistently for follow-up. * A minimal pain score of 5 measured by both NRS and VAS when walking last week. * Knee pain on most days (no less than 15 days) in the 4 weeks before screening * Patients have experienced that NSAID or opioid pain medication failed to control knee pain in the last year. * Patients have experienced that a single intra-articular injection of medicines, such as steroids, hyaluronic acid, or platelet-rich plasma, failed to control the knee pain over 6 months. * Non-invasive treatments did not control the knee pain. Conservative and non-invasive treatment regimens may include any or all of the following: initial rest, muscle relaxants, massage, and oral medications, e.g., anti-inflammatory drugs, analgesics, narcotics/opioids. * The patients have taken supervised physical and rehabilitation therapy, such as daily walking routines, therapeutic exercises, sonication, heat/cold therapy, and electric stimulation for knee pain control within the last year. Exclusion Criteria: * Patients who have taken knee, distal femur, or proximal tibia surgery. * Patients who took an intra-articular injection of medicine, such as steroids, hyaluronic acid, or platelet-rich plasma, in the last 3 months. * Reduced joint space width at the lateral part of the knee compared to the medial part under x-ray examination. * Patients who have severe varus deformity and tibiofemoral alignments are larger than 20 degrees. * Patients who cannot cooperate with the two-year follow-up. * Patients who have had tumor, infection, or trauma at the time of recruitment. * Patients with abnormal blood routine test, such as severe anemia, leukemia, sepsis, platelet dysfunction, or other blood-related diseases. * Patients who cannot agree to the withdrawal of non-steroid anti-inflammatory drugs (NSAIDs) or opioids during the trial period. * Patients who cannot cooperate with blood drawing. * The body mass index (BMI) value of the patient is higher than 30. * Female subjects who are pregnant, breastfeeding, planning to become pregnant, or unable to cooperate in contraception during the trial. * Subjects with a history of neurocognitive disorders, or those who have sought neurological consultation due to suspected dementia or memory decline * History of post-traumatic osteoarthritis. * History of rheumatoid arthritis, gouty arthritis, spontaneous osteonecrosis of the knee (SONK), or hemophilia. * Employees or family members of the PI and co-PI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Chiayi

    Chiayi City, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.